MTOR and Cerebral ischemia: In this study, we investigated whether Rapalink-1, a third-generation mTOR inhibitor, would inhibit both mTORC1 and mTORC2 and its effects on neuronal survival and BBB disruption in cerebral ischemia–reperfusion.